• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $NBIX

    Neurocrine Biosciences Inc.

    Subscribe to $NBIX
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

    IPO Year: 1996

    Exchange: NASDAQ

    Website: neurocrine.com

    Recent Analyst Ratings for Neurocrine Biosciences Inc.

    DatePrice TargetRatingAnalyst
    7/21/2025$163.00Buy
    Truist
    7/10/2025$182.00Buy
    Goldman
    4/15/2025$138.00Hold → Buy
    Needham
    4/14/2025$137.00Sector Perform → Outperform
    RBC Capital Mkts
    2/11/2025$138.00Hold
    Deutsche Bank
    10/10/2024$155.00Outperform
    Raymond James
    8/29/2024$131.00 → $159.00Neutral → Overweight
    Piper Sandler
    4/24/2024$140.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    12/13/2023$127.00Neutral
    Citigroup
    12/12/2023$136.00Buy
    Deutsche Bank
    See more ratings

    Neurocrine Biosciences Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Regulatory Officer Delaet Ingrid exercised 457 shares at a strike of $79.02 and sold $61,695 worth of shares (457 units at $135.00) (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      7/11/25 5:15:12 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Onyia Jude exercised 59,819 shares at a strike of $84.74 and sold $7,803,688 worth of shares (59,819 units at $130.46) (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      7/11/25 5:01:03 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Onyia Jude sold $2,649,738 worth of shares (20,362 units at $130.13) and exercised 20,362 shares at a strike of $84.74 (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      7/7/25 4:10:27 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Keswani Sanjay Chandru

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      6/4/25 5:37:41 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Keswani Sanjay Chandru

      3 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      6/4/25 5:34:40 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Gorman Kevin Charles sold $1,157,211 worth of shares (9,613 units at $120.38), decreasing direct ownership by 2% to 514,596 units (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      5/29/25 6:15:13 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Rastetter William H converted options into 2,869 shares, increasing direct ownership by 8% to 40,360 units (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      5/22/25 6:15:50 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Poon Christine A converted options into 1,435 shares (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      5/22/25 5:32:07 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gorman Kevin Charles

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      5/22/25 5:29:54 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sharp Shalini converted options into 1,435 shares, increasing direct ownership by 144% to 2,429 units (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      5/22/25 5:28:01 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Neurocrine Biosciences Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

      For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con

      12/13/24 5:54:17 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Neurocrine Biosciences Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Neurocrine Biosciences with a new price target

      Truist initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $163.00

      7/21/25 8:37:42 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Neurocrine Biosciences with a new price target

      Goldman initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $182.00

      7/10/25 8:58:47 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences upgraded by Needham with a new price target

      Needham upgraded Neurocrine Biosciences from Hold to Buy and set a new price target of $138.00

      4/15/25 7:52:35 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Neurocrine Biosciences from Sector Perform to Outperform and set a new price target of $137.00

      4/14/25 8:05:29 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Neurocrine Biosciences with a new price target

      Deutsche Bank initiated coverage of Neurocrine Biosciences with a rating of Hold and set a new price target of $138.00

      2/11/25 7:09:50 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James resumed coverage on Neurocrine Biosciences with a new price target

      Raymond James resumed coverage of Neurocrine Biosciences with a rating of Outperform and set a new price target of $155.00

      10/10/24 8:37:58 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Neurocrine Biosciences from Neutral to Overweight and set a new price target of $159.00 from $131.00 previously

      8/29/24 7:34:42 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Neurocrine Biosciences from Equal Weight to Overweight and set a new price target of $170.00 from $140.00 previously

      4/24/24 6:18:56 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Citigroup resumed coverage on Neurocrine Biosciences with a new price target

      Citigroup resumed coverage of Neurocrine Biosciences with a rating of Neutral and set a new price target of $127.00

      12/13/23 8:05:39 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Neurocrine Biosciences with a new price target

      Deutsche Bank initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $136.00

      12/12/23 7:59:10 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Neurocrine Biosciences Inc. SEC Filings

    See more
    • Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/30/25 4:05:10 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/22/25 4:03:59 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Neurocrine Biosciences Inc.

      S-8 POS - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/21/25 5:28:04 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Neurocrine Biosciences Inc.

      S-8 POS - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/21/25 5:27:14 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Neurocrine Biosciences Inc.

      S-8 POS - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/21/25 5:26:09 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Neurocrine Biosciences Inc.

      S-8 POS - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/21/25 5:25:27 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Neurocrine Biosciences Inc.

      S-8 POS - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/21/25 5:24:37 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Neurocrine Biosciences Inc.

      S-8 POS - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/21/25 5:23:42 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Neurocrine Biosciences Inc.

      S-8 POS - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/21/25 5:22:33 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Neurocrine Biosciences Inc.

      S-8 POS - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/21/25 5:20:58 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Neurocrine Biosciences Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition

      Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia SAN FRANCISCO, July 15, 2025 /PRNewswire/ -- PicnicHealth, a health technology company dedicated to advancing the next generation of non-interventional research, today announced its research collaboration with Neurocrine Biosciences, Inc. (NASDAQ:NBIX), the CAHtalog® Registry, identified an unmet need in patients with classic congenital adrenal hyperplasia (CAH). Using PicnicHealth's AI-powered technology to curate medical records and enable remote participation, the study revealed that CAH patients require lifelong, continuous adjustments to glucocorticoid dosing

      7/15/25 9:00:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025

      Approximately 95% of adult and pediatric patients were exposed to supraphysiologic doses of glucocorticoids and/or experienced elevated androstenedione levels at least once during their treatment journeyReal-world findings underscore long-term challenges of managing classic congenital adrenal hyperplasia and highlight clinical need for therapies to reduce androgen excess without high glucocorticoid dosesSAN DIEGO, July 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced results from a new analysis using real-world data from CAHtalog®, a comprehensive registry of patients with classic congenital adrenal hyperplasia in the United States. The analysis demonstrate

      7/15/25 8:30:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting

      Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductionsSubstantial improvements in insulin resistance were also observed in both adult and pediatric patients treated with CRENESSITY compared with placebo through one year of treatmentSAN DIEGO, July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the presentation of new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies showing favorable trends in improvement of weight-related outcomes in patients with classic congenital adrenal hyperplasia who were treated with CRENESSITY® (crinecerfont) for

      7/14/25 4:35:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025

      One-year data from CAHtalyst™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasiaResults build upon previously reported one-year data from CAHtalyst™ Pediatric studySAN DIEGO, July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the presentation of new one-year data from the CAHtalyst™ Adult study of CRENESSITY® (crinecerfont) showing that patients achieved lasting, more physiologic glucocorticoid doses, while adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained at or below baseline levels. These data complement the recently

      7/14/25 8:30:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results

      Conference Call and Webcast Scheduled for Wednesday, July 30 SAN DIEGO, July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2025. The schedule for the press release and conference call / webcast is as follows: Q2 2025 Press Release: July 30, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ2 2025 Conference Call: July 30, 2025 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-225-9448Internat

      7/9/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist

      SAN DIEGO, June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants. NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia (CAH). "As a leader in CAH, Neurocrine is dedicated to expanding treatment

      6/30/25 4:05:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

      Patient-reported analyses demonstrated greater reduction in both cognitive and motor-related disease burden for INGREZZA compared with placeboFindings to be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders (ATMRD) CongressSAN DIEGO, June 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced new patient-reported post-hoc data from the KINECT®-HD study highlighting significant reductions in both cognitive and motor-related burdens among adults treated for Huntington's disease chorea with once-daily INGREZZA® (valbenazine) capsules. KINECT-HD is the first and only clinical study to demonstrate measurable changes in cognitive and motor dis

      6/27/25 8:30:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia

      Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at the 2025 American Association of Nurse Practitioners (AANP) National Conference SAN DIEGO, June 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study demonstrating significant patient-reported improvements in health-related quality of life and functional measures among adults aged 65 years and older with tardive dyskinesia who received continued treatment with INGREZZA® (valbenazine) capsules. Findings will be prese

      6/20/25 8:30:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

      SAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. "Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change," said Matt Abernethy, Chief Finan

      6/9/25 4:05:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia

      KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scalesPatients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional functioningImprovements were seen as early as Week 4 after initial treatment with the lowest INGREZZA dose and sustained through Week 24Even patients with milder uncontrolled movement severity were negatively impacted by their tardive dyskinesia at baseline and demonstrated meaningful improvements in tardive dyskinesia impact with INGREZZA treatmentSAN

      6/2/25 8:30:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Neurocrine Biosciences Inc. Financials

    Live finance-specific insights

    See more
    • Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results

      Conference Call and Webcast Scheduled for Wednesday, July 30 SAN DIEGO, July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2025. The schedule for the press release and conference call / webcast is as follows: Q2 2025 Press Release: July 30, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ2 2025 Conference Call: July 30, 2025 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-225-9448Internat

      7/9/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

      INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms Initiated Phase 3 Registrational Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia to Position for Next Phase of Growth SAN DIEGO, May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial guidance.

      5/5/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results

      Conference Call and Webcast Scheduled for Monday, May 5 SAN DIEGO, April 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its first quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2025. The schedule for the press release and conference call / webcast is as follows: Q1 2025 Press Release: May 5, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ1 2025 Conference Call: May 5, 2025 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-245-3047International Dial

      4/14/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

      INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont), a First-in-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia, Approved and Launched in the United States Phase 3 Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia Initiating in the First Half of 2025 SAN DIEGO, Feb. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the fourth quart

      2/6/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

      Conference Call and Webcast Scheduled for Thursday, February 6 SAN DIEGO, Jan. 30, 2025 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 6, 2025. The schedule for the press release and conference call / webcast is as follows: Q4 & Year-End 2024 Press Release: February 6, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ4 & Year-End 2024 Conference Call: February 6, 2025 at 1:30 p.m. PT / 4:30 p.m. E

      1/30/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

      INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO, Oct. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the third quarter ended September 30, 2024 and provided an update on its 2024 financial guidance. "With continued INGREZZA growth across the tardive dyskinesia and Huntington's disease chorea indications,

      10/30/24 7:00:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

      Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on October 30, 2024. The schedule for the press release and conference call / webcast is as follows: • Q3 2024 Press Release:          October 30, 2024 at 4:00 a.m. PT / 7:00 a.m. ET • Q3 2024 Conference Call:        October 30, 2024 at 5:00 a.m. PT / 8:00 a.m. ET • Domestic D

      10/9/24 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

      NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine BiosciencesThe once-daily 20 mg dose efficacy, safety and tolerability Phase 2 results support advancement to Phase 3 in schizophrenia in early 2025The once-daily 20 mg dose met the primary endpoint, demonstrating a statistically significant 7.5-point improvement (p=0.011, 0.61 effect size) in the PANSS total score compared to placebo at week 6 with an 18.2-point PANSS total score improvement from baselineThe once-daily 20 mg dose met additional endpoints, demonstrating statistically significant improvements in Clinica

      8/28/24 7:07:37 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia

      The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week 6 with an 18.2-Point PANSS Total Score Improvement from BaselineThe Once-Daily 20 mg Dose Met Additional Endpoints, Demonstrating Statistically Significant Improvements in Clinical Global Impression of Severity Scale and Marder Factor Score Positive Symptom Change and Negative Symptom ChangeNBI-'568 Was Generally Safe and Well Tolerated at All Doses StudiedThe Once-Daily 20 mg Dose Efficacy, Safety and Tolerability Phase 2 Results Support Advancement to Phase 3 in Schizophrenia in Early 2025Company

      8/28/24 7:00:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

      INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion Top-Line Phase 2 Data Readouts for NBI-'568 and Luvadaxistat Remain On Track in Q3 SAN DIEGO, Aug. 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the second quarter ended June 30, 2024 and provided an update on its 2024 financial guidance. "At Neurocrine, we are energized by the tremendous opportunity we see to help many

      8/1/24 7:00:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Neurocrine Biosciences Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

      SAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. "Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change," said Matt Abernethy, Chief Finan

      6/9/25 4:05:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

      SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

      5/30/25 4:30:14 PM ET
      $FATE
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

      Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an accomplished physician-scientist who has more than 20 years of pharmaceutical industry experience with broad R&D expertise in multiple therapeutic areas, will lead the clinical development and medical affairs activities at Neurocrine. Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as C

      4/4/25 8:00:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Announces CEO Succession Plan

      Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D., to continue to serve on the Neurocrine Board of Directors SAN DIEGO, May 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX), today announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024. Kyle Gano, Ph.D., currently Neurocrine's Chief Business Development and Strategy Officer, will succeed him in the CEO role. Dr. Gano will also join the Company's Board of Directors at that time, and Dr. Gorman will continue to serve on the Neurocrine Board.

      5/28/24 4:14:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors

      SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors. "Christine Poon brings a wealth of industry experience to Neurocrine's Board of Directors," said William H. Rastetter, Chairman of the Board of Neurocrine Biosciences. "Her strong track record in leadership positions at some of the most established global biopharmaceutical enterprises will serve Neurocrine well." Ms. Poon has demonstrated br

      7/11/23 4:05:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer

      SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr. Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021. "Ingrid's deep experience in regulatory affairs will be invaluable to Neurocrine as we work to advance our pipeline in our quest to relieve suffering for people with

      9/29/22 11:00:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer

      SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that Jude Onyia, Ph.D., has joined the company's executive management team as Chief Scientific Officer. Dr. Onyia, a scientist with more than 25 years of experience in the pharmaceutical industry, will lead the drug discovery and non-clinical development teams responsible for bolstering and advancing the company's pipeline of therapeutic candidates. Dr. Onyia most recently was the Chief Scientific Officer at Capsida Biotherapeutics. Prior to that, he spent 25 years at Eli Lilly

      11/30/21 4:05:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors

      SAN DIEGO, April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Officer of Gilead Sciences, with responsibility for the global commercialization of Gilead's medicines. "We are pleased to add Johanna Mercier to the Board of Directors at Neurocrine Biosciences," said William H. Rastetter, Chairman of the Board of Neurocrine Biosciences. "Johanna is an accomplished commercial leader and her extensive global experience within the biopharmaceutical

      4/16/21 9:00:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Neurocrine Biosciences Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Neurocrine Biosciences Inc.

      SC 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      10/17/24 9:54:01 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

      SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      2/9/23 11:27:44 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

      SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      2/14/22 2:34:19 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Neurocrine Biosciences, Inc. (Amendment)

      SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      8/10/21 10:33:18 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      2/16/21 12:23:41 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      2/10/21 11:28:21 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      2/8/21 10:29:25 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care